Closer Look at CXCR4 Antagonists: A Promising Future for Cancer Patients
CXCR4 antagonists are drugs that block the CXCR4 receptor, a protein associated with cancer spread and HIV/AIDS. AMD 3100, which is also known as plerixafor, is the most widely used CXCR4 antagonist that has been approved to mobilize the stem cells of hematopoietic origin in cancer patients. Other potential CXCR4 antagonists are mavorixafor (XOLREMDI) and BL-8040. XOLREMDI was recently launched...
0 Commentarii 0 Distribuiri 67 Views 0 previzualizare